Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.
Collignon A, Hospital MA, Montersino C, Courtier F, Charbonnier A, Saillard C, D'Incan E, Mohty B, Guille A, Adelaïde J, Carbuccia N, Garnier S, Mozziconacci MJ, Zemmour C, Pakradouni J, Restouin A, Castellano R, Chaffanet M, Birnbaum D, Collette Y, Vey N. Collignon A, et al. Among authors: zemmour c. Blood Cancer J. 2020 Jun 3;10(6):64. doi: 10.1038/s41408-020-0330-5. Blood Cancer J. 2020. PMID: 32488055 Free PMC article. Clinical Trial.
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.
Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Chaffanet M. Letessier A, et al. Among authors: zemmour c. BMC Cancer. 2006 Oct 13;6:245. doi: 10.1186/1471-2407-6-245. BMC Cancer. 2006. PMID: 17040570 Free PMC article.
JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia.
De Grandis M, Bardin F, Fauriat C, Zemmour C, El-Kaoutari A, Sergé A, Granjeaud S, Pouyet L, Montersino C, Chretien AS, Mozziconacci MJ, Castellano R, Bidaut G, Boher JM, Collette Y, Mancini SJC, Vey N, Aurrand-Lions M. De Grandis M, et al. Among authors: zemmour c. Cancer Res. 2017 Dec 1;77(23):6627-6640. doi: 10.1158/0008-5472.CAN-17-1223. Epub 2017 Sep 28. Cancer Res. 2017. PMID: 28972073
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Bouchacourt B, Hospital MA, Zemmour C, Rey J, d'Incan E, Charbonnier A, Mohty B, Saillard C, Bonnet S, Collignon A, Gelsi-Boyer V, Mozziconacci MJ, Blaise D, Vey N. Bouchacourt B, et al. Among authors: zemmour c. Ann Hematol. 2020 Apr;99(4):773-780. doi: 10.1007/s00277-020-03922-w. Epub 2020 Feb 22. Ann Hematol. 2020. PMID: 32088745
TRAINING-Ovary 01 (connecTed pRehabiliAtIoN pelvIc caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected pre-habilitation program.
Lambaudie E, Bannier/Braticevic C, Villaron/Goetgheluck C, Zemmour C, Boher JM, Ben Soussan P, Pakradouni J, Brun C, Lopez Almeida L, Marino P. Lambaudie E, et al. Among authors: zemmour c. Int J Gynecol Cancer. 2021 Jun;31(6):920-924. doi: 10.1136/ijgc-2020-002128. Epub 2020 Dec 1. Int J Gynecol Cancer. 2021. PMID: 33262113 Clinical Trial.
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
Noel R, Zemmour C, Montes de Oca C, Belmecheri N, Aurran-Schleinitz T, Coso D, Lopez Almeida L, Mescam L, Vey N, Bladé JS, Slama B, Bouabdallah R, Schiano de Colella JM. Noel R, et al. Among authors: zemmour c. Hematology. 2023 Dec;28(1):2207948. doi: 10.1080/16078454.2023.2207948. Hematology. 2023. PMID: 37133334 Clinical Trial.
Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal M, Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A. Sabatier R, et al. Among authors: zemmour c. Cancer Res Treat. 2018 Oct;50(4):1226-1237. doi: 10.4143/crt.2017.446. Epub 2017 Dec 28. Cancer Res Treat. 2018. PMID: 29281873 Free PMC article.
Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.
Gravis G, Autret A, Guibert-Broudic M, Dubergé T, Zemmour C, Carrier P, Salem N, Badinand D, Cartier L, Gross E, Walz J, Pignot G, Brenot-Rossi I. Gravis G, et al. Among authors: zemmour c. Clin Genitourin Cancer. 2021 Aug;19(4):346-353. doi: 10.1016/j.clgc.2021.03.004. Epub 2021 Mar 16. Clin Genitourin Cancer. 2021. PMID: 33849812
57 results